Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Jansen

Showing results (651-660 of 703) with videos related to

Pageof 71
Sort By:
Rheumatology (Oxford, England)|January 31, 2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locusFaseeh Zaidi, Ravi K Narang, Amanda Phipps-Green, et al.
Plos One|December 24, 2010
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcomeMarieke J H Coenen, Christian Enevold, Pilar Barrera, et al.
Annals of the Rheumatic Diseases|July 27, 2016
2016 updated EULAR evidence-based recommendations for the management of goutP Richette, M Doherty, E Pascual, et al.
Arthritis Care & Research|July 11, 2017
Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of DiseaseMarjan Ghiti Moghadam, Peter M Ten Klooster, Harald E Vonkeman, et al.
Molecular Oncology|January 31, 2025
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnosticsGuy Froyen, Pieter-Jan Volders, Ellen Geerdens, et al.
Annals of the Rheumatic Diseases|April 12, 2007
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceW Kievit, J Fransen, A J M Oerlemans, et al.
International Journal of Cancer|October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocolIlse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
BMC Immunology|November 20, 2014
The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseasesJaap Ten Oever, Matthijs Kox, Frank L van de Veerdonk, et al.
International Journal of Clinical Oncology|December 6, 2017
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The NetherlandsJohannes J M Kwakman, G Vink, J H Vestjens, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2026
BRAF<sup>V600E</sup>-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery ProtocolSoemeya F Haj Mohammad, Ilse A C Spiekman, Karlijn Verkerk, et al.
Pageof 71

Showing results (651-660 of 703) with videos related to

Sort By:
Pageof 71
Rheumatology (Oxford, England)|January 31, 2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locusFaseeh Zaidi, Ravi K Narang, Amanda Phipps-Green, et al.
Plos One|December 24, 2010
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcomeMarieke J H Coenen, Christian Enevold, Pilar Barrera, et al.
Annals of the Rheumatic Diseases|July 27, 2016
2016 updated EULAR evidence-based recommendations for the management of goutP Richette, M Doherty, E Pascual, et al.
Arthritis Care & Research|July 11, 2017
Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of DiseaseMarjan Ghiti Moghadam, Peter M Ten Klooster, Harald E Vonkeman, et al.
Molecular Oncology|January 31, 2025
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnosticsGuy Froyen, Pieter-Jan Volders, Ellen Geerdens, et al.
Annals of the Rheumatic Diseases|April 12, 2007
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceW Kievit, J Fransen, A J M Oerlemans, et al.
International Journal of Cancer|October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocolIlse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
BMC Immunology|November 20, 2014
The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseasesJaap Ten Oever, Matthijs Kox, Frank L van de Veerdonk, et al.
International Journal of Clinical Oncology|December 6, 2017
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The NetherlandsJohannes J M Kwakman, G Vink, J H Vestjens, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2026
BRAF<sup>V600E</sup>-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery ProtocolSoemeya F Haj Mohammad, Ilse A C Spiekman, Karlijn Verkerk, et al.
Pageof 71